| Literature DB >> 34835953 |
Alaina P Vidmar1,2, Monica Naguib1,2, Jennifer K Raymond1,2, Sarah Jeanne Salvy3, Elizabeth Hegedus1,2, Choo Phei Wee4, Michael I Goran1,2.
Abstract
Due to its simplicity, time-limited eating (TLE) may represent a more feasible approach for treating adolescents with obesity compared to other caloric restriction regimens. This pilot study examines the feasibility and safety of TLE combined with continuous glucose monitoring (CGM) in adolescents. Fifty adolescents with BMI ≥95th percentile were recruited to complete a 12-week study. All received standard nutritional counseling, wore a CGM daily, and were randomized to: (1) Prolonged eating window: 12 h eating/12 h fasting + blinded CGM; (2) TLE (8 h eating/16 h fasting, 5 days per week) + blinded CGM; (3) TLE + real-time CGM feedback. Recruitment, retention, and adherence were recorded as indicators of feasibility. Weight loss, dietary intake, physical activity, eating behaviors, and quality of life over the course of the intervention were explored as secondary outcomes. Forty-five participants completed the study (16.4 ± 1.3 years, 64% female, 49% Hispanic, 75% public insurance). There was high adherence to prescribed eating windows (TLE 5.2 d/wk [SD 1.1]; control 6.1 d/wk [SD 1.4]) and daily CGM wear (5.85 d/wk [SD 4.8]). Most of the adolescents (90%) assigned to TLE reported that limiting their eating window and wearing a CGM was feasible without negative impact on daily functioning or adverse events. There were no between-group difference in terms of weight loss, energy intake, quality of life, physical activity, or eating behaviors. TLE combined with CGM appears feasible and safe among adolescents with obesity. Further investigation in larger samples, with a longer intervention duration and follow-up assessments are needed.Entities:
Keywords: adolescents; continuous glucose monitor; intermittent fasting; obesity; pediatrics
Mesh:
Year: 2021 PMID: 34835953 PMCID: PMC8624400 DOI: 10.3390/nu13113697
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Demographic characteristics and baseline anthropometrics.
| Total | Control | TLE + Blinded CGM | TLE + Real-Time CGM Feedback |
| |
|---|---|---|---|---|---|
| Age (in year) 1 | 16.43 ± 1.17 | 16.38 ± 1.25 | 16.16 ± 1.16 | 16.80 ± 1.09 | 0.3 a |
| Sex 2 | 0.8 b | ||||
| Male | 14 (28.0) | 3 (20.0) | 6 (31.5) | 5 (31.2) | |
| Female | 36 (72.0) | 12 (80.0) | 13 (68.4) | 11 (68.7) | |
| Race 2 | 0.05 b | ||||
| White | 5 (10.0) | 3 (20.0) | 1 (5.2) | 1 (6.0) | |
| Black | 3 (6.0) | 1 (6.6) | 2 (10.5) | 0 (0) | |
| Asian | 4 (8.0) | 3 (20.0) | 1 (5.2) | 0 (0) | |
| Hispanic | 27 (54.0) | 7 (46.7) | 13 (68.4) | 7 (43.8) | |
| Am. Indian | 2 (4.0) | 0 (0) | 1 (5.2) | 1 (6.2) | |
| Mixed race | 6 (12.0) | 1 (6.6) | 0 (0) | 5 (31.2) | |
| Ethnicity 2 | 0.1 b | ||||
| Non-Hispanic | 15 (30.0) | 8 (53.3) | 4 (21.1) | 3 (18.7) | |
| Hispanic | 32 (64.0) | 7 (46.6) | 14 (73.6) | 11 (68.7) | |
| Weight (kg) 3 | 101.4 | 104.3 | 99.5 | 110.5 | 0.9 c |
| %BMIp95 3 | 125.9 | 141.1 | 122.6 | 123.9 | 0.9 c |
| BMI z-score 1 | 2.30 ± 0.5 | 2.34 ± 0.5 | 2.28 ± 0.4 | 2.30 ± 0.5 | 0.9 a |
a Analysis of variance; b Fisher’s Exact test; c Analysis of variance in log scale; 1 Mean ± standard deviation; 2 Frequency (percentage); 3 Median (interquartile range).
Figure 1Consolidated Standards of Reporting Trials (CONSORT) flow diagram of participant inclusions.
Mean number of days (SD) in which the assigned eating window was completed across intervention arms using intention to treat with carry forward of the last weeks data.
| Week | Control ( | TLE + Blinded CGM ( | TLE + Real-Time CMG Feedback ( |
|---|---|---|---|
| 1 | 5.1 (1.9) | 4.03 (1.9) | 4.5 (1.9) |
| 2 | 5.6 (1.3) | 5.3 (1.3) | 5.3 (1.2) |
| 3 | 5.6 (1.3) | 5.4 (1.3) | 6.7 (1.3) |
| 4 | 6.1 (1.6) | 5.1 (1.6) | 5.3 (1.4) |
| 5 | 5.9 (1.6) | 5.1 (1.6) | 5.4 (1.7) |
| 6 | 4.9 (1.3) | 5.4 (1.3) | 5.9 (1.1) |
| 7 | 6.7 (1.3) | 5.3 (1.3) | 6.0 (1.0) |
| 8 | 5.4 (1.1) | 5.4 (1.1) | 4.9 (1.1) |
| 9 | 5.9 (1.0) | 5.1 (1.0) | 4.8 (1.5) |
| 10 | 6.1 (1.2) | 5.3 (1.2) | 5.3 (1.4) |
| 11 | 5.5 (1.5) | 5.3 (1.5) | 5.1 (1.0) |
| 12 | 4.9 (1.0) | 5.3 (1.0) | 4.9 (1.1) |
Figure 2Percent weight loss at week 12 compared to baseline by individual participants across: (a) all three intervention arms and (b) TLE groups (TLE + blinded CGM and TLE + real-time CGM) compared to control.
Weight change between baseline and week 12 across intervention arms.
| Weight Change | Control ( | TLE + Blinded CGM ( | TLE + Real-Time CGM Feedback ( |
| Effect Size |
|---|---|---|---|---|---|
| BMI z-score change | −0.05 ± 0.09 | −0.09 ± 0.14 | −0.11 ± 0.19 | 0.6 | 0.04 |
| %BMIp95 change | −3.27 ± 3.34 | −3.76 ± 5.76 | −4.85 ± 5.08 | 0.7 | 0.04 |
Gamma mixed-effects generalized linear model on %BMIp95 and BMI z-score.
| %BMIp95 | % Change | 95% CI |
|
|---|---|---|---|
|
| |||
| 0 | Ref | -- | -- |
| 4 | −2.0 | (−2.7, −1.3) | <0.0001 |
| 8 | −2.9 | (−3.8, −1.9) | <0.0001 |
| 12 | −3.3 | (−4.4, −2.1) | <0.0001 |
|
| |||
| Control | Ref | -- | -- |
| TLE + blinded CGM | −3.4 | (−17.6, 13.3) | 0.7 |
| TLE + real-time CGM feedback | −4.3 | (−17.9, 11.7) | 0.6 |
|
| β | 95% CI |
|
|
| |||
| 0 | Ref | -- | -- |
| 4 | −0.05 | (−0.1, −0.03) | <0.0001 |
| 8 | −0.08 | (−0.1, −0.04) | <0.0001 |
| 12 | −0.09 | (−0.1, −0.05) | <0.0001 |
|
| |||
| Control | Ref | -- | -- |
| TLE + blinded CGM | −0.08 | (−0.4, 0.2) | 0.6 |
| TLE + real-time CGM feedback | −0.06 | (−0.4, 0.3) | 0.7 |
Figure 3Weight change across the study period by intervention group for (a) change in excess percent of the 95th percentile (%BMIp95) and (b) change in BMI z-score.
Mixed-effects generalized linear model of the glycemic profile change extracted from CGM data.
| Glycemic Profile | β | 95% CI |
|
|---|---|---|---|
| Average blood glucose | |||
|
| |||
| 0 | Ref | ||
| 4 | 2.7 | (−4.3, 9.7) | 0.4 |
| 8 | 3.3 | (−3.6, 10.3) | 0.3 |
| 12 | 3.3 | (−7.9, 14.6) | 0.6 |
|
| |||
| Control | Ref | ||
| TLE + blinded CGM | −4.2 | (−14.7, 6.1) | 0.4 |
| TLE + real-time feedback | −7.1 | (−20.2, 6.0) | 0.2 |
| Estimated HbA1c | |||
|
| |||
| 0 | Ref | ||
| 4 | 0.1 | (−0.1, 0.3) | 0.3 |
| 8 | 0.1 | (−0.1, 0.3) | 0.3 |
| 12 | 0.1 | (−0.2, 0.4) | 0.5 |
|
| |||
| Control | Ref | ||
| TLE + blinded CGM | −0.2 | (−0.5, 0.1) | 0.2 |
| TLE + real-time feedback | −0.3 | (−0.7, 0.1) | 0.2 |